Abstracts tagged "ACPA"

Abstract Number: 815 • 2014 ACR/ARHP Annual Meeting
Netosis Induced Histone Citrullination Facilitates Onset and Propagation of Rheumatoid Arthritis
Dong Hyun Sohn¹, Kazuhiro Onuma¹, Chris Rhodes¹, Xioayan Zhao¹, Tal Gazitt², Rani Shiao¹, Justyna Fert Bober³, Danye Cheng¹, Lauren J. Lahey¹, Heidi Wong⁴, Jennifer van Eyk³, William H. Robinson^1,5 and Jeremy Sokolove¹, ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²Rheumatology, University of Washington, Seattle, WA, ³Johns Hopkins University and Cedars Sinai Medical Center, Los Angeles, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are characteristic of rheumatoid arthritis however, their presence years before onset of clinical RA is perplexing. Although multiple putative…
Abstract Number: 123 • 2014 ACR/ARHP Annual Meeting
Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis
Yohei Kirino¹, Maasa Hama¹, Kaoru Minegishi-Takase¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Atsushi Ihata², Shigeru Ohno³, Atsuhisa Ueda¹, Mitsuhiro Takeno⁴ and Ishigatsubo Yoshiaki¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ³Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁴Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose , Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments. We here evaluated the use…
Abstract Number: 2918 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations
Yukinori Okada¹, Kwangwoo Kim², Buhm Han³, Nisha E. Pillai⁴, Rick T-H. Ong⁴, Woei-Yuh Saw⁴, Ma Luo⁵, Lei Jiang⁶, Jian Yin⁶, So-Young Bang⁷, Hye-Soon Lee⁷, Matthew A. Brown⁸, Sang-Cheol Bae², Huji Xu⁹, Yik-Ying Teo⁴, Paul IW. de Bakker¹⁰ and Soumya Raychaudhuri³, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴National University of Singapore, Singapore, Singapore, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶The Second Military Medical University, Shanghai, China, ⁷Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁸University of Queensland Diamantina Institute, Brisbane, Australia, ⁹Shanghai Changzheng Hospital, Shanghai, China, ¹⁰Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) risk is strongly associated with variations within the major histocompatibility complex (MHC) region, and in particular to HLA-DRB1 alleles. We aimed…
Abstract Number: 441 • 2014 ACR/ARHP Annual Meeting
Arthritis Associated Autoantibodies in Non-Rheumatoid Arthritis Patients with Mucosal Inflammation
Koen M. J. Janssen¹, Menke J. de Smit², Elisabeth Brouwer³, Berber Doornbos-van der Meer³, Arie Jan van Winkelhoff^2,4, Arjan Vissink⁵, Josje Altenburg⁶, Nivine Levarht⁷, Marije K. Verheul⁷, Leendert A. Trouw⁷ and Johanna Westra³, ¹Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Center for Dentistry and Oral Hygiene, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁶Department of Pulmonary Diseases, Medical Center Alkmaar, Alkmaar, Netherlands, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) associated autoantibodies, such as anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP), can be present in serum…
Abstract Number: 2797 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis
Akilan Krishnamurthy¹, Vijay Joshua¹, Heidi Wähämaa¹, Catia Cerqueira¹, Lars Klareskog², Vivianne Malmström³, Jimmy Ytterberg¹ and Anca I Catrina¹, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Presence of anti-citrullinated protein antibodies (ACPA) is a major risk factor for bone erosion in rheumatoid arthritis (RA) and antibodies against modified citrullinated vimentin…
Abstract Number: 450 • 2014 ACR/ARHP Annual Meeting
The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis
Anneke van der Horst¹, Ivy Y.K. Choi², Dirkjan van Schaardenburg³, D.M Gerlag², Paul Tak², Dörte Hamann¹ and Rogier M. Thurlings², ¹Sanquin Diagnostic Services, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Recent data suggest rheumatoid arthritis (RA) may originate from an autoimmune response in inflamed mucosa. RA is associated with gingival and airway inflammation and…
Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression
Marshall Davis¹, Tricia LeVan², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Kaleb Michaud⁷, Geoffrey M Thiele⁸ and Ted R. Mikuls⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Univ of Nebraska Med Ctr, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷National Data Bank for Rheumatic Diseases, Wichita, KS, ⁸Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA). In this study,…
Abstract Number: 449 • 2014 ACR/ARHP Annual Meeting
Citrullinated-Vimentin-Specific Regulatory T-Cell Responses Associate with ACPA Positive Individuals with Non-Specific Musculoskeletal Symptoms
Aamir Aslam¹, Jackie L. Nam¹, Laura Hunt¹, Chadi Rakieh¹, Ann W. Morgan² and Paul Emery¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: The pathogenesis of RA can be conceptualised by sequential phases that precede the development of synovitis. Autoimmune antibody responses, including ACPA, can precede clinical…
Abstract Number: 2019 • 2014 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen Are Associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis
Jan M. Hughes-Austin¹, Ryan W. Gan², Kevin D. Deane³, Peter K. Gregersen⁴, Michael H. Weisman⁵, Joachim H. Ix⁶, Jeremy Sokolove⁷, William H. Robinson⁸, V. Michael Holers⁹ and Jill M. Norris², ¹Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University of California, San Diego, La Jolla, CA, ⁷VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁸VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Hypertension is common in rheumatoid arthritis (RA), but it is unclear whether this prevalence is due to RA-related medications or to the disease process…
Abstract Number: 448 • 2014 ACR/ARHP Annual Meeting
Citrulline-Specific Autoimmunity Resides in Quiescent Circulating Memory B Cells in Rheumatoid Arthritis
Adam Pelzek, Caroline Grönwall, Jeffrey D. Greenberg and Gregg J. Silverman, Medicine, New York University School of Medicine, New York, NY
Background/Purpose . The detection of anti-citrullinated protein antibodies (ACPA) aids RA diagnosis, while B cell depletion by anti-CD20 can provide clinical benefits. We therefore undertook…
Abstract Number: 1740 • 2014 ACR/ARHP Annual Meeting
Predicting the Evolution of Inflammatory Arthritis in ACPA-Positive Individuals: Can T-Cell Subsets Model Help?
Laura Hunt¹, Agata Burska², Elizabeth M.A. Hensor¹, Jackie L. Nam¹, Frederique Ponchel¹ and Paul Emery¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom
Background/Purpose: ACPA+ individuals with non-specific musculoskeletal symptoms are at high risk of developing rheumatoid arthritis (RA). We previously demonstrated dys-regulation of T-cell subsets with loss…
Abstract Number: 447 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm³, Johan Rönnelid³, Lars Klareskog² and Solbritt Rantapää-Dahlqvist⁴, ¹Public Health & Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden
Background/Purpose The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) has been shown to precede the development of rheumatoid arthritis (RA) by…
Abstract Number: 1738 • 2014 ACR/ARHP Annual Meeting
Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA
Sandra M.J. Paulissen¹, Jan Piet van Hamburg², Nadine Davelaar², Heleen Vroman³, Johanna MW Hazes⁴, P.H.P. de Jong⁵ and Erik Lubberts², ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Presence of serum anti-citrullinated protein antibodies (ACPAs) in patients with rheumatoid arthritis (RA) predicts worse disease course and a more erosive disease. In the…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting
Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients
Shikha Singla¹, Minzi Chen², Jerry Pounds Jr.², Omar Khan², Jerald M. Zakem², Kismet Collins², Tamika Webb-Detiege², William E. Davis², Robert Quinet² and Xin Zhang³, ¹Rheumatology, Ochner Medical Center, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.